Delving into the Latest Updates on Gonadotropins (Xentria) with Synapse

Overview

Basic Info

Drug Type

Hormone

Synonyms-

Target-

Action

modulators

Mechanism

FSH modulators(Follicle-stimulating hormone modulators)

Therapeutic Areas

Urogenital Diseases

Active Indication

Pregnancy

Inactive Indication-

Originator Organization

Xentria, Inc.

Active Organization

Xentria, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

INTRODUCTIONOvarian hyperstimulation syndrome (OHSS) is a potentially severe complication of ovulation induction. Although less common than with gonadotropin treatment, OHSS can occur secondary to an excessive dose of clomiphene citrate, a first-line ovulation induction agent. A serious complication of OHSS is ovarian torsion, which demands prompt diagnosis and intervention to prevent permanent damage. This case report highlights a rare case of severe ovarian hyperstimulation syndrome (OHSS) with subsequent ovarian torsion following clomiphene citrate treatment.CASE PRESENTATIONA 24-year-old woman with primary infertility developed severe OHSS after receiving clomiphene citrate (100 mg twice daily, D2-D16). Her initial symptoms included vomiting and severe abdominal pain. Ultrasound examination revealed an enlarged left ovary (100x65x60mm) with multiple follicles and pelvic effusion. Despite initial conservative management, the patient returned four days post-discharge with worsening symptoms. Emergency laparoscopy revealed vascular congestion of the left ovary and successful detorsion restored normal blood flow.CASE DISCUSSIONthis case illustrates severe OHSS complicated by ovarian torsion secondary to an excessive dose of clomiphene citrate. The patient's initial presentation and ultrasound findings were indicative of OHSS, and despite conservative management, progression to ovarian torsion required surgical intervention. The successful detorsion and restoration of blood flow underscore the importance of timely surgical management to prevent irreversible damage, regardless of the ovulation induction agent used.CONCLUSIONAlthough clomiphene citrate is generally considered safer than gonadotropins for ovulation induction, it can still induce severe OHSS leading to complications such as ovarian torsion particularly if given in overdosage. This case emphasizes the critical need for vigilant monitoring and prompt surgical intervention in OHSS cases to preserve ovarian function, regardless of the ovulation induction agent used.

17 Mar 2025·The Journal of Clinical Endocrinology & Metabolism

Gonadotropin Therapy for Mini-Puberty Induction in Male Infants With Hypogonadotropic Hypogonadism

Review

Author: Alexander, Emma C ; Rohayem, Julia ; Rhys-Evans, Sophie ; Howard, Sasha R ; Heger, Sabine ; Dinah, Ibrahim F ; d’Aniello, Francesco ; Nordenstrom, Anna

AbstractContextCongenital hypogonadotropic hypogonadism (CHH) is defined as an isolated deficiency of gonadotropin hormones. Mini-puberty, a transient postnatal activation of the hypothalamic-pituitary-gonadal axis in healthy infants, provides a window of opportunity to diagnose and treat CHH. Currently, in male infants with CHH, testosterone is used to increase phallus size. However, gonadotropin replacement could additionally promote testicular descent and development, particularly relating to Sertoli cells. We conducted a systematic review of the effectiveness of gonadotropin therapy in stimulating mini-puberty related outcomes in male infants with CHH.Evidence AcquisitionIn line with PRISMA guidelines, a systematic review of 11 databases was carried out (August 2023). Evidence quality was assessed using the Cochrane Risk of Bias for Non-Randomised Studies of Interventions tool. Protocol registered on PROSPERO (CRD42023453080).Evidence SynthesisAfter a double-consensus screen of 767 abstracts and 66 full texts, 11 studies were included from 7 countries. A total of 71 male infants were enrolled, 12 with Kallmann syndrome. Median age at treatment initiation was 4.2 months (range, 0.25-57 months) and follow-up ranged from 3 to 10 years. Gonadotropin therapy was administered using continuous subcutaneous infusion (n = 35) or subcutaneous injection (n = 36). Due to treatment variability, modalities were combined for data synthesis. Gonadotropins induced a statistically significant increase in penile length and inhibin B concentration (P = .0007) and led to partial or full testicular descent in 73% (n = 62) of patients.ConclusionThis systematic review provides unique evidence supporting the efficacy of gonadotropins for induction of mini-puberty. However, the reliability and generalizability are limited due to disparate data and treatment modality variation.

01 Feb 2025·Journal of Obstetrics and Gynaecology Research

Comparison of clomiphene citrate + letrozole add‐on versus classical ovarian stimulation protocols in diminished ovarian reserve patients

Article

Author: Tunç, Mehmet ; Önalan, Göğşen

AbstractAimTo investigate if there is any benefit of adding clomiphene citrate (CC) + letrozole to controlled ovarian stimulation (COS) cycles on the total gonadotropin dose in POSEIDON group 4 diminished ovarian reserve (DOR) patients.MethodsA total of 61 DOR patients who underwent 150 COS cycles between 2020 and 2023 in our center were investigated retrospectively. The patients were divided into three main subgroups: group A, group B, and group C. In group A, gonadotropin stimulation started after the completion of 5 days of co‐treatment with CC (50 mg twice daily) and letrozole (2.5 mg twice daily). In group B, patients received gonadotropins after completing 5 days of letrozole (2.5 mg twice, daily), and in group C, patients started gonadotropins only.ResultsMean age was higher in groups A and B. Body mass index, previous parity, and mean AMH levels were similar between the groups. Day 2 antral follicle count was significantly lower in group A (0.90, 1.45 and 1.53; p = 0.017). The need for gonadotropins was lower in group A compared to groups B and C (p = 0.131, and p = 0.029; respectively). Cycle cancellation rates, follicle count on trigger day, number of mature oocytes, number of cleavage stage embryos, and number of blastocyst stage embryos were similar between the groups.ConclusionCC + letrozole co‐treatment before starting gonadotropin stimulation in POSEIDON group 4 DOR patients might reduce the need for gonadotropins, with similar live birth rates in COS cycles.

100 Deals associated with Gonadotropins (Xentria)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Preclinical	United States	Xentria, Inc.	19 Oct 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data